

GLAXOSMITHKLINE PLC

Form 6-K

July 19, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 19 July 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons
- b) Position/status SVP, Global Ethics & Compliance
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument ('ADSs')
GlaxoSmithKline plc
American Depositary Shares
ISIN: US37733W1053

- b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018.

- c) Price(s) and volume(s)
Price(s) Volume(s)
\$41.1815 18.276

- d) Aggregated information n/a (single transaction)

- e) Aggregated volume Price
Date of the transaction 2018-07-17

- f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer Healthcare
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053

	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s) Volume(s) \$41.1815 412.270
Aggregated information	
d)	n/a (single transaction)
Aggregated volume	Price
e) Date of the transaction	2018-07-17
f) Place of the transaction	New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D E Troy
b) Position/status	SVP & General Counsel
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
--------------------------------------------	-----------------------------------------------------------

	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s) Volume(s) \$41.1815 2206.084
Aggregated information	
d)	n/a (single transaction)
Aggregated volume	Price
e) Date of the transaction	2018-07-17
f) Place of the transaction	New York Stock Exchange (XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 19, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc